These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30063807)

  • 1. Omalizumab for the treatment of chronic spontaneous urticaria in daily clinical practice in South Spain.
    Ruiz-Villaverde R; Pereyra-Rodriguez JJ; Hernández-Montoya C; Galán-Gutierrez M; Alcantara-Luna S; Lara-Jimenez MA
    Dermatol Ther; 2018 Sep; 31(5):e12669. PubMed ID: 30063807
    [No Abstract]   [Full Text] [Related]  

  • 2. Responsiveness and minimal important difference of the urticaria control test.
    Ohanyan T; Schoepke N; Bolukbasi B; Metz M; Hawro T; Zuberbier T; Peveling-Oberhag A; Staubach P; Maurer M; Weller K
    J Allergy Clin Immunol; 2017 Dec; 140(6):1710-1713.e11. PubMed ID: 28625805
    [No Abstract]   [Full Text] [Related]  

  • 3. Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice.
    Bongiorno MR; Crimi N; Corrao S; Allotta A; Arena A; Brusca I; Heffler E; Malara G; Milioto M; Pistone G; Porto M; Raia E; Valenti G
    Ann Allergy Asthma Immunol; 2016 Dec; 117(6):703-707. PubMed ID: 27720581
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of omalizumab in severe chronic spontaneous urticaria: Real life data from a Greek tertiary center.
    Kyriakou A; Trigoni A; Sotiriadis D; Patsatsi A
    Dermatol Ther; 2018 Nov; 31(6):e12739. PubMed ID: 30194796
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term omalizumab therapy for refractory chronic spontaneous urticaria: a real-life experience.
    Ensina LF; de Lacerda AE; Machado LM; Camelo-Nunes I; Solé D
    Ann Allergy Asthma Immunol; 2015 Dec; 115(6):536. PubMed ID: 26653279
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are the effects of omalizumab in refractory chronic spontaneous urticaria?
    López M; Navajas-Galimany L
    Medwave; 2015 Dec; 15 Suppl 3():e6346. PubMed ID: 26731420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Home self-administration of omalizumab for chronic spontaneous urticaria.
    Denman S; Ford K; Toolan J; Mistry A; Corps C; Wood P; Savic S
    Br J Dermatol; 2016 Dec; 175(6):1405-1407. PubMed ID: 27639259
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
    Giménez-Arnau AM; Toubi E; Marsland AM; Maurer M
    J Eur Acad Dermatol Venereol; 2016 Jul; 30 Suppl 5():25-32. PubMed ID: 27286500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab in An 8-Year-Old Boy With Diabetes Mellitus and Refractory Chronic Spontaneous Urticaria.
    Jesenak M; Ciljakova M; Janickova M; Banovcin P
    J Investig Allergol Clin Immunol; 2019 Apr; 29(2):144-146. PubMed ID: 31017115
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic spontaneous urticaria in an 8-year-old girl treated with omalizumab.
    Ossorio-García L; Jiménez-Gallo D; Albarrán-Planelles C; Arjona-Aguilera C; Linares-Barrios M
    Clin Exp Dermatol; 2016 Dec; 41(8):929-930. PubMed ID: 27761937
    [No Abstract]   [Full Text] [Related]  

  • 12. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria.
    Koski R; Kennedy KK
    Ann Allergy Asthma Immunol; 2017 Nov; 119(5):397-401. PubMed ID: 29150066
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.
    Saini SS; Omachi TA; Trzaskoma B; Hulter HN; Rosén K; Sterba PM; Courneya JP; Lackey A; Chen H
    J Invest Dermatol; 2017 Apr; 137(4):958-961. PubMed ID: 27939380
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria.
    Sánchez J; Zakzuk J; Cardona R
    J Allergy Clin Immunol Pract; 2018; 6(1):177-182.e1. PubMed ID: 28709817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urticaria control test might misevaluate disease control in particular patients treated with omalizumab.
    Türk M; Yılmaz İ
    Ann Allergy Asthma Immunol; 2019 Mar; 122(3):342-343. PubMed ID: 30529015
    [No Abstract]   [Full Text] [Related]  

  • 17. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
    Giménez-Arnau AM
    Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria.
    Ferrer M; Boccon-Gibod I; Gonçalo M; İnalöz HS; Knulst A; Lapeere H; Parthasaradhi A; Stingl G; Tagka A; Valenzuela F; Yeung J; Thomsen SF
    Eur J Dermatol; 2017 Oct; 27(5):455-463. PubMed ID: 29084635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Idiopathic Urticaria.
    Wu EY; Saini SS
    J Allergy Clin Immunol Pract; 2015; 3(6):1003-4; quiz 105. PubMed ID: 26553623
    [No Abstract]   [Full Text] [Related]  

  • 20. Omalizumab for chronic spontaneous urticaria: a boon for sufferers, but there are unanswered questions.
    Greaves MW
    Br J Dermatol; 2015 Aug; 173(2):321. PubMed ID: 26346076
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.